KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Common Equity (2016 - 2025)

Boston Scientific's Common Equity history spans 17 years, with the latest figure at $24.2 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 10.13% year-over-year to $24.2 billion; the TTM value through Dec 2025 reached $24.2 billion, up 10.13%, while the annual FY2025 figure was $24.2 billion, 10.13% up from the prior year.
  • Common Equity for Q4 2025 was $24.2 billion at Boston Scientific, up from $21.2 billion in the prior quarter.
  • Across five years, Common Equity topped out at $24.2 billion in Q4 2025 and bottomed at -$2.3 billion in Q4 2022.
  • The 5-year median for Common Equity is $16.5 billion (2021), against an average of $10.4 billion.
  • The largest annual shift saw Common Equity soared 10801.99% in 2021 before it crashed 13341.18% in 2024.
  • A 5-year view of Common Equity shows it stood at $16.5 billion in 2021, then crashed by 113.67% to -$2.3 billion in 2022, then surged by 967.61% to $19.5 billion in 2023, then grew by 12.66% to $22.0 billion in 2024, then grew by 10.13% to $24.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Common Equity are $24.2 billion (Q4 2025), $21.2 billion (Q2 2025), and -$28.0 million (Q1 2025).